EPLERAF-Study: Eplerenone in the prevention of atrial fibrillation recurrences after cardioversion.
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2015
At a glance
- Drugs Eplerenone (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms EPLERAF
- 09 Feb 2012 Actual patient number 38 added as reported by ClinicalTrials.gov.
- 09 Feb 2012 Planned end date changed from 1 Mar 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 09 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.